Intrexon | XON - Operating Expenses


Intrexon reported $61.56M in Operating Expenses for its fiscal quarter ending in June of 2024.





Operating Expenses Change Date
Agenus USD -199.08M 22.15M Jun/2026
Alaunos Therapeutics USD 1.01M 175K Mar/2026
Amgen USD 11.69B 6.9B Jun/2026
Anika Therapeutics USD 137.28M 3.38M Jun/2026
Arrowhead Research USD 245.35M 30.35M Jun/2026
AstraZeneca USD 12.22B 4.04B Jun/2026
Bristol-Myers Squibb USD 23.4B 1.08B Sep/2026
Gilead Sciences USD 13.04B 9.09B Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Incyte USD 5.64B 4.67B Sep/2026
Intrexon USD 61.56M 26.1M Jun/2024
Karyopharm Therapeutics USD 61.83M 9.9M Mar/2026
Ligand Pharmaceuticals USD 94.5M 39.4M Sep/2026
MacroGenics USD 42.87M 21.68M Jun/2026
MannKind USD 110.21M 690K Jun/2026
Merck USD 10.75B 5.02B Sep/2026
Novartis USD 10.2B 912M Jun/2026
Rigel Pharmaceuticals USD 117.61M 35.67M Sep/2025
Roche Holding CHF 18.9B 2.12B Jun/2026
Sangamo BioSciences USD 33.87M 12.89M Jun/2024
Thermo Fisher Scientific USD 9.68B 134M Sep/2026
Veracyte USD 126.36M 6.37M Jun/2026
Xencor USD 87.82M 5.44M Jun/2026